Valeant Plunges for Second Day as Analyst Says ‘Too Much Risk’

  • Wells Fargo writes 2nd note after rating stock `underperform'
  • Adding to concerns is uncertainty about earnings release date

Valeant Pharmaceuticals International Inc. slumped as much as 15 percent, the biggest drop since November, as a selloff extended to a second day after a Wells Fargo analyst added to his negative report about the company.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.